Exclusion of a P53 Germline Mutation in a Classic Li-Fraumeni Syndrome Family
Affiliations
Li-Fraumeni syndrome (LFS) is characterized by a high risk of sarcomas, early onset of breast cancer, and a diversity of other cancers occurring as multiple primary tumors in multiple family members. In many families with LFS, germline mutations within the tumor-suppressor gene p53 have been identified. However, mutations in p53 have not been detected in approximately 30% of LFS families. To address the possibility either that p53 mutations were being missed or that another predisposing gene is altered in LFS, we used a variety of methods to accurately determine the p53 status in a large LFS kindred. A transcriptional activation assay on exons 4-10 of p53 excluded a mutation within the DNA-binding domain of p53. Single-stranded conformational-polymorphism analysis, using intronic primers and sequencing of all the coding exons and intron/exon junctions, also yielded no mutations. Finally, linkage analysis excluded potential mutations in the noncoding regions of p53. Our findings exclude the presence of a p53 germline mutation in a classic LFS family.
Intronic TP53 Germline Sequence Variants Modify the Risk in German Breast/Ovarian Cancer Families.
Liu X, Sinn H, Ulmer H, Scott R, Hamann U Hered Cancer Clin Pract. 2010; 2(3):139-45.
PMID: 20233468 PMC: 4392522. DOI: 10.1186/1897-4287-2-3-139.
High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.
Valentin-Vega Y, Barboza J, Chau G, El-Naggar A, Lozano G Hum Pathol. 2007; 38(10):1553-62.
PMID: 17651783 PMC: 2699677. DOI: 10.1016/j.humpath.2007.03.005.
Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour.
Scott R, Stiller C, Walker L, Rahman N J Med Genet. 2006; 43(9):705-15.
PMID: 16690728 PMC: 2564568. DOI: 10.1136/jmg.2006.041723.
Generation or birth cohort effect on cancer risk in Li-Fraumeni syndrome.
Brown B, Costello T, Hwang S, Strong L Hum Genet. 2005; 118(3-4):489-98.
PMID: 16284780 DOI: 10.1007/s00439-005-0016-x.
A novel genetic modifier of p53, mop1, results in embryonic lethality.
Evans S, Liang M, Amos C, Gu X, Lozano G Mamm Genome. 2004; 15(6):415-23.
PMID: 15181534 DOI: 10.1007/s00335-004-2327-y.